Related Experiment Videos
Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon
E A El-Gabry1, S E Strup, L G Gomella
1Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Techniques in Urology
|August 30, 2000
Summary
Antiandrogen withdrawal syndrome is known, but a sustained undetectable prostate-specific antigen (PSA) response after stopping bicalutamide is novel. This case highlights a potential durable PSA decline with bicalutamide discontinuation in prostate cancer management.
Area of Science:
- Oncology
- Urology
- Pharmacology
Background:
- Antiandrogen withdrawal syndrome is a documented phenomenon with nonsteroidal antiandrogen agents.
- Prostate-specific antigen (PSA) is a key biomarker in prostate cancer management.
- Bicalutamide is a commonly used nonsteroidal antiandrogen medication.
Observation:
- A patient experienced a significant decline in serum PSA levels.
- This decline was observed after the discontinuation of bicalutamide therapy.
- The PSA levels became undetectable following the cessation of the drug.
Findings:
- This case presents the first reported instance of a durable undetectable PSA response after discontinuing bicalutamide.
- The findings suggest a potential benefit of antiandrogen withdrawal in managing PSA levels.
- The study focuses on the specific antiandrogen agent bicalutamide.
Implications:
- Discontinuation of bicalutamide may lead to a sustained undetectable PSA response in some patients.
- This observation could influence treatment strategies for prostate cancer.
- Further research is warranted to explore the antiandrogen withdrawal syndrome with bicalutamide and its long-term effects.